Follow
Kelly Holloway
Kelly Holloway
Assistant Professor (status), University of Toronto
Verified email at utoronto.ca
Title
Cited by
Cited by
Year
Too few, too weak: conflict of interest policies at Canadian medical schools
A Shnier, J Lexchin, B Mintzes, A Jutel, K Holloway
PloS one 8 (7), e68633, 2013
542013
Conflict of interest as ethical shorthand: understanding the range and nature of “non-financial conflict of interest” in biomedicine
Q Grundy, C Mayes, K Holloway, S Mazzarello, BD Thombs, L Bero
Journal of clinical epidemiology 120, 1-7, 2020
382020
Blood donation and the global COVID‐19 pandemic: areas for social science research
J Haw, K Holloway, BM Masser, EM Merz, R Thorpe
Vox Sanguinis 116 (4), 363, 2021
372021
Normalizing complaint: Scientists and the challenge of commercialization
KJ Holloway
Science, Technology, & Human Values 40 (5), 744-765, 2015
372015
Half a century of Wilson & Jungner: reflections on the governance of population screening
S Sturdy, F Miller, S Hogarth, N Armstrong, P Chakraborty, C Cressman, ...
Wellcome Open Research 5, 2020
252020
Uneasy subjects: Medical students' conflicts over the pharmaceutical industry
K Holloway
Social Science & Medicine 114, 113-120, 2014
212014
‘Something there is that doesn’t love a wall’: Histories of the placental barrier
A Martin, K Holloway
Studies in History and Philosophy of Science Part C: Studies in History and …, 2014
202014
Health Canada needs to act on laboratory-developed diagnostics
K Holloway, FA Miller, F Rousseau, A Gutierrez, S Hogarth
CMAJ 191 (39), E1067-E1069, 2019
172019
A responsibility to commercialize? Tracing academic researchers’ evolving engagement with the commercialization of biomedical research
KHM Herder
Journal of Responsible Innovation, 2019
172019
Industry, experts and the role of the ‘invisible college’in the dissemination of non-invasive prenatal testing in the US
K Holloway, FA Miller, N Simms
Social science & medicine 270, 113635, 2021
132021
Dangerous diagnostics? Regulatory reform in the genomic era
K Holloway, FA Miller, A Gutierrez, S Hogarth
BMJ 364, 2019
92019
Understanding the experiences of plasma donors in Canada's new source plasma collection centres during COVID‐19: A qualitative study
K Holloway
Vox Sanguinis, 2022
72022
Blood collection agency messaging to donors and the public in Canada and Australia during the early days of covid-19
J Haw, R Thorpe, K Holloway
Frontiers in Communication 6, 777829, 2022
72022
The Consultant's intermediary role in the regulation of molecular diagnostics in the US
K Holloway, FA Miller
Social science & medicine 304, 112929, 2022
62022
The Market in Noninvasive Prenatal Tests and the Message to Consumers: Exploring Responsibility
K Holloway, N Simms, RZ Hayeems, FA Miller
Hastings Center Report 52 (2), 49-57, 2022
52022
Teaching conflict: Professionalism and medical education
KJ Holloway
Journal of bioethical inquiry 12, 675-685, 2015
52015
How do we forecast tomorrow’s transfusion? Applying social science approaches to meet tomorrow’s transfusion needs: Blood donors and donation
J Haw, K Holloway, M Goldman
Transfusion Clinique et Biologique 30 (1), 47-51, 2023
12023
What influences decisions to donate plasma? A rapid review of the literature
M Berger, A Easterbrook, K Holloway, D Devine, N Bansback
Vox Sanguinis, 2023
12023
A Troubled Solution: Medical Student Struggles with Evidence and Industry Bias
KJ Holloway
Science and engineering ethics 21, 1673-1689, 2015
12015
Patient advocacy, drug promotion, and the feminist paradox: An analysis of the Canadian Pain Coalition
K Holloway, J Haw
Health Tomorrow: Interdisciplinarity and Internationality 1 (1), 2013
12013
The system can't perform the operation now. Try again later.
Articles 1–20